CHEMEX CHX 108 ANTI-PSORIATIC WILL BEGIN CLINICALS WITHIN "ABOUT A MONTH,"
Executive Summary
CHEMEX CHX 108 ANTI-PSORIATIC WILL BEGIN CLINICALS WITHIN "ABOUT A MONTH," becoming the company's third drug to reach the human test stage. Chemex announced at its annual meeting Sept. 22 in Denver that it has filed an IND for CHX 108. The new chemical entity "will be investigated for treatment of psoriasis and other inflammatory conditions of the skin," Chemex said. Already in clinicals for actinic keratosis are two antitumor drugs, CHX 100 and CHX 2053. CHX 100 is currently in Phase II. The Denver-based company has said that it expects to complete Phase III study of CHX 2053 and file an NDA for the compound by the end of 1988 ("The Pink Sheet" Aug. 24, T&G-4). Chemex also announced a drug evaluation and licensing agreement with Squibb at its annual meeting. "The agreement allows Chemex to evaluate certain drugs already under development or registered by Squibb to determine if these compounds might be of use in the treatment of skin diseases and disorders," the company said in a news release. If the Squibb compounds "show promise as possible dermatological products, Chemex has the right to develop and market these pharmaceuticals to dermatologists," the release stated. "The Squibb agreement is part of our company's business strategy to shorten the development time and accelerate market introduction of new skin care therapies," said Chemex President Edward Neiss, MD.